Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bitopertin for persistent, predominant negative symptoms of schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bitopertin (bitopertin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED